NCT05836701

Brief Summary

Retrospectively analyzing the epidemiological and clinical characteristics, treatment, recurrence, prognosis and prognostic factors of the germ-cell tumors of central nervous system in a single center.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2023

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 19, 2023

Completed
12 days until next milestone

First Posted

Study publicly available on registry

May 1, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

June 1, 2023

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

October 15, 2024

Status Verified

October 1, 2024

Enrollment Period

1.6 years

First QC Date

April 19, 2023

Last Update Submit

October 9, 2024

Conditions

Germ Cell Tumor of CNS

Outcome Measures

Primary Outcomes (4)

  • epidemiological characteristics

    1 year

  • treatment regimen

    1 year

  • relapse pattern

    1 year

  • prognostic factor

    1 year

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Sanbo Brain Hospital, Capital Medical University

You may qualify if:

  • Clinically or pathologically diagnosed as germ cell tumor of the central nervous system.
  • Have received antitumor therapy.
  • Patients who were clinically diagnosed based on neuroimaging characteristics and response to radiotherapy or chemotherapy were allowed for enrollment.

You may not qualify if:

  • Patients with missing key information such as tumor location, surgical, chemotherapy and radiotherapy data, and post-treatment evaluation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sanbo Brain Hospital Capital Medical University

Beijing, China

Location

Study Officials

  • Jun-ping Zhang

    Capital Medical University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Neuro-Oncology

Study Record Dates

First Submitted

April 19, 2023

First Posted

May 1, 2023

Study Start

June 1, 2023

Primary Completion

December 31, 2024

Study Completion

December 31, 2024

Last Updated

October 15, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)